{"id":"NCT00421148","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961)","officialTitle":"A Multi-Center, Randomized, Parallel Dose-Finding, Safety Assessor-Blinded Trial to Explore the Efficacy, Safety and Pharmacokinetics of Four Doses of Org 25969 and Placebo in Pediatric and Adult Subjects.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05-30","primaryCompletion":"2006-05-31","completion":"2006-06-02","firstPosted":"2007-01-11","resultsPosted":"2019-01-28","lastUpdate":"2019-01-28"},"enrollment":94,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Anesthesia"],"interventions":[{"type":"DRUG","name":"Sugammadex 0.5 mg/kg","otherNames":["Org 25969","MK-8616","SCH 900616"]},{"type":"DRUG","name":"Sugammadex 1 mg/kg","otherNames":["Org 25969","MK-8616","SCH 900616"]},{"type":"DRUG","name":"Sugammadex 2 mg/kg","otherNames":["Org 25969","MK-8616","SCH 900616"]},{"type":"DRUG","name":"Sugammadex 4 mg/kg","otherNames":["Org 25969","MK-8616","SCH 900616"]},{"type":"DRUG","name":"Placebo","otherNames":["sodium chloride 0.9% solution"]},{"type":"DRUG","name":"Rocuronium bromide","otherNames":["ESMERONÂ®"]}],"arms":[{"label":"Sugammadex 0.5 mg/kg","type":"EXPERIMENTAL"},{"label":"Sugammadex 1 mg/kg","type":"EXPERIMENTAL"},{"label":"Sugammadex 2 mg/kg","type":"EXPERIMENTAL"},{"label":"Sugammadex 4 mg/kg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is:\n\n* to explore the dose-response relation of sugammadex (Org 25969, MK-8616, SCH 900616) given as a reversal agent at reappearance of T2 after 0.6 mg.kg-1 rocuronium in pediatric and adult participants\n* to explore the pharmacokinetics (PK) of sugammadex in pediatric and adult participants, and to evaluate the safety of sugammadex in pediatric and adult participants.","primaryOutcome":{"measure":"Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.9","timeFrame":"From start of sugammadex or palcebo administration to recovery of T4/T1 ratio to 0.9 (ranging from ~0.5 minutes to ~30 minutes from sugammadex or placebo administration)","effectByArm":[{"arm":"Infants: Placebo","deltaMin":20.98,"sd":11.3},{"arm":"Infants: Sugammadex 0.5 mg/kg","deltaMin":3.72,"sd":0.63},{"arm":"Infants: Sugammadex 1 mg/kg","deltaMin":2.42,"sd":0.7},{"arm":"Infants: Sugammadex 2 mg/kg","deltaMin":0.58,"sd":null},{"arm":"Children: Placebo","deltaMin":19.57,"sd":10.97},{"arm":"Children: Sugammadex 0.5 mg/kg","deltaMin":5.22,"sd":3.5},{"arm":"Children: Sugammadex 1 mg/kg","deltaMin":3.95,"sd":3.23},{"arm":"Children: Sugammadex 2 mg/kg","deltaMin":1.2,"sd":0.35},{"arm":"Children: Sugammadex 4 mg/kg","deltaMin":1.57,"sd":1.9},{"arm":"Adolescents: Placebo","deltaMin":22.77,"sd":13.1},{"arm":"Adolescents: Sugammadex 0.5 mg/kg","deltaMin":11.97,"sd":17.65},{"arm":"Adolescents: Sugammadex 1 mg/kg","deltaMin":1.77,"sd":0.37},{"arm":"Adolescents: Sugammadex 2 mg/kg","deltaMin":1.87,"sd":1.7},{"arm":"Adolescents: Sugammadex 4 mg/kg","deltaMin":1.08,"sd":0.25},{"arm":"Adults: Placebo","deltaMin":29.48,"sd":8.43},{"arm":"Adults: Sugammadex 0.5 mg/kg","deltaMin":3.77,"sd":1.12},{"arm":"Adults: Sugammadex 1 mg/kg","deltaMin":1.62,"sd":0.3},{"arm":"Adults: Sugammadex 2 mg/kg","deltaMin":1.27,"sd":0.27},{"arm":"Adults: Sugammadex 4 mg/kg","deltaMin":1.37,"sd":0.38},{"arm":"Infants: Sugammadex 4 mg/kg","deltaMin":0.67,"sd":null}],"pValues":[]},"eligibility":{"minAge":"28 Days","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["19194156"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":2},"commonTop":["Procedural pain","Vomiting","Nausea","Constipation","Pain"]}}